支气管动脉化疗栓塞术联合<sup>125</sup>I放射性粒子植入术治疗非小细胞肺癌的疗效

doi:10.3969/j.issn.1671-7171.2025.12.023

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1230 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the efficacy of bronchial artery chemoembolization (BACE) combined with ¹²⁵I seed implantation in the treatment of non-small cell lung cancer (NSCLC). 【Methods】 A total of 82 NSCLC patients were randomly divided into a control group (gemcitabine plus cisplatin chemotherapy) and an observation group (BACE combined with ¹²⁵I seed implantation), with 41 cases in each group. Clinical efficacy, tumor diameter, pulmonary function indices, cancer pain scores, frailty scores, and adverse reactions were compared between the two groups before and after treatment. 【Results】 The clinical response rate in the observation group (80.49%) was higher than that in the control group (51.22%) (P<0.05). After treatment, tumor diameter, cancer pain scores, and frailty scores in the observation group were lower than those in the control group (P<0.05). Forced vital capacity, forced expiratory volume in 1 second, and maximal voluntary ventilation were all higher in the observation group than in the control group (P<0.05). The incidences of nausea, vomiting, alopecia, and grade Ⅰ-Ⅳ myelosuppression in the observation group were lower those in the group group (P<0.05). 【Conclusion】 BACE combined with ¹²⁵I seed implantation can significantly improve the clinical efficacy in NSCLC patients, reduce tumor size, improve pulmonary function, alleviate cancer pain and frailty, and reduce adverse reactions.

Key words： Carcinoma, Non-Small-Cell Lung Bronchial Arteries Iodine Radioisotopes Chemoembolization, Therapeutic Treatment Outcome

Received: 13 June 2025

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.12.023 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I12/2097

[1] CAO W,CHEN H D,YU Y W,et al.Changing profiles of cancerburden worldwide and in China:a secondary analysis of theglobal cancer statistics 2020[J].Chin Med J(Engl),2021,134:783-791.
[2] 梁超,李浩,韩大千,等.支气管动脉灌注化疗栓塞联合替雷利珠单抗治疗晚期非小细胞肺癌的有效性与安全性[J].介入放射学杂志,2025,34(2):148-153.
[3] 张志辉.支气管动脉化疗栓塞与全身静脉化疗治疗中晚期非小细胞肺癌的临床效果比较[J].中华养生保健,2025,43(5):51-55.
[4] KUNISADA K,ISHIKAWA H,TAKAFUJI J,et al.A case of a 91-year-old patient with advanced squamous cell lung cancer complicated with renal dysfunction successfully treated with trans-arterial chemo-embolization[J].Gan To Kagaku Ryoho,2013,40:917-919.
[5] 李广,刘勇,郭贺贺,等.¹²⁵I放射性粒子植入治疗对老年非小细胞肺癌患者癌性疼痛的影响[J].癌症进展,2024,22(13):1444-1447.
[6] 陆舜,虞永峰,纪文翔.2015年肺癌诊疗指南:共识和争议[J].解放军医学杂志,2016,41(1):1-6.
[7] 张萍,艾斌.实体瘤免疫治疗疗效评价标准[J].国际肿瘤学杂志,2016,43(11):848-851.
[8] 孙兵,车晓明.视觉模拟评分法(VAS)[J].中华神经外科杂志,2012,42(6):645.
[9] SEGAL J B,CHANG H Y,DU Y,et al.Development of a claimsbased frailty indicator anchored to a well-established frailty phenotype[J].Med Care,2017,55(7):716-722.
[10] 佘华龙,陈凯.表皮生长因子受体酪氨酸激酶抑制剂联合¹²⁵I放射性粒子植入治疗非小细胞肺癌的效果[J].中国医药导报,2020,17(8):121-124.
[11] 李香强.CT引导下¹²⁵I粒子植入联合支气管动脉化疗栓塞治疗非小细胞肺癌患者的临床效果研究[J].影像研究与医学应用,2025,9(10):12-14.
[12] 余龙伍,华双一,李春,等.经支气管等动脉化疗栓塞对70岁以上非手术老年肺癌患者的效果[J].中外医学研究,2024,22(21):143-146.
[13] 张邢柯,田应选,孙莉.老年综合评估在老年癌症患者疼痛管理中的应用进展[J].现代肿瘤医学,2021,29(3):528-530.
[14] 陈志瑾,贡桔,夏宁,等.CT四维电磁导航引导¹²⁵I放射性粒子植入治疗肺门旁非小细胞肺癌的应用研究[J].中国临床医学影像杂志,2020,31(8):551-554.
[15] 冯江峰,赵振华,王挺,等.¹²⁵I放射性粒子植入联合支气管动脉灌注化疗治疗晚期非小细胞肺癌效果及安全性的Meta分析[J].中国医药科学,2022,12(8):37-41.